Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

We explored the impact of early molecular response (EMR; BCR-ABL ≤10% on the international scale [BCR-ABL(IS)] at 3 or 6 months) on outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with nilotinib or imatinib based on 4 years of follow up in Evaluating Nilot...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Hughes, Timothy P., Saglio, Giuseppe, Kantarjian, Hagop M., Guilhot, François, Niederwieser, Dietger, Rosti, Gianantonio, Nakaseko, Chiaki, De Souza, Carmino Antonio, Kalaycio, Matt E., Meier, Stephan, Fan, Xiaolin, Menssen, Hans D., Larson, Richard A., Hochhaus, Andreas
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624459/
https://ncbi.nlm.nih.gov/pubmed/24335106
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-06-510396
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados